TrialCancer medicine2013

Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen.

Brent Blumenstein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.